pxl065

PXL065 is a novel, proprietary deuterium-stabilized R-enantiomer of pioglitazone developed for the treatment of nonalcoholic steatohepatitis (NASH) and X-linked adrenoleukodystrophy (X-ALD). Unlike racemic pioglitazone or its S-enantiomer, PXL065 lacks significant peroxisome proliferator-activated receptor gamma (PPARγ) agonist activity and therefore avoids side effects such as weight gain and edema. Its mechanism of action involves inhibition of the mitochondrial pyruvate carrier (MPC) and acyl-CoA synthetase 4 (ACSL4), targeting non-genomic pathways to reduce oxidative stress, inflammation, and fibrosis. PXL065 has demonstrated efficacy in preclinical models for NASH and X-ALD as well as in a Phase 2 clinical trial for NASH where it reduced liver fat without causing weight gain or edema. The drug was originally discovered by DeuteRx using deuterium-enabled chiral switching technology before being acquired by Poxel.

Other names

d-R-pioglitazoneDRX-065DRX065DRX 065